Company-wide revenue
Reported revenue in 2021 ¥559M Reported revenue in 2025 ¥429M
- growth amount
- −¥130M
- growth annualized
- -6.4%
- growth total
- -23.3%
Japanese company profile · 4597
Soreijiafuaama
In its FY2025 public filing, Soreijiafuaama reports Development and Sales of Pharmaceuticals and Related Products. The page shows business-level revenue and profit where the source disclosures support comparison.
Romanized spelling of the Japanese company name; not an official English name.
Original Japanese company name: ソレイジア・ファーマ株式会社
Reported company-wide figures
What does this company do?
What does this company do?
Soreijiafuaama's largest reported business by revenue in FY2025 was Development and Sales of Pharmaceuticals and Related Products.
FY2025 · fiscal year ended December 2025 View original filing ↗ The source document may be in Japanese.
Business structure
How does it make money?
| Business | Segment revenue | Revenue share | Segment profit (loss) |
|---|---|---|---|
| Development and Sales of Pharmaceuticals and Related Products | ¥429M ↗ | 100.0% | −¥861M ↗ |
All values are in Japanese yen (JPY). No currency conversion is applied. FY2025 · fiscal year ended December 2025. Revenue and profit are shown only where the filing and data support a comparison.
Original Japanese label
- Development and Sales of Pharmaceuticals and Related Products
- 医薬品等の開発及び販売
- Segment revenue
- セグメント収益
- Segment profit (loss)
- セグメント利益（損失）
Original Japanese label
- Development and Sales of Pharmaceuticals and Related Products
- 医薬品等の開発及び販売
- Segment revenue
- セグメント収益
- Segment profit (loss)
- セグメント利益（損失）
Reported Segment revenue by business over time
Reported Segment revenue by business over time
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Development and Sales of Pharmaceuticals and Related Products | ¥559M | ¥1.09B | ¥617M | ¥316M | ¥429M |
All amounts are in Japanese yen (JPY). Each figure links to the original Japanese filing. Blank cells indicate no comparable figure was disclosed. Business figures may not add up to consolidated figures.
What is growing?
What is growing?
Business revenue growth
Development and Sales of Pharmaceuticals and Related Products
Reported revenue in 2021 ¥559M Reported revenue in 2025 ¥429M
- growth amount
- −¥130M
- growth annualized
- -6.4%
- growth total
- -23.3%
View original filing
This describes a reported period; it is not a forecast.
What has changed?
What has changed?
Not disclosed or not safely comparable in the available filings.
Source
Public filing
FY2025 · fiscal year ended December 2025
The source document may be in Japanese.
Filing ID: S100XT68
View original filing ↗Ask about this company
Ask about this company
The source document may be in Japanese.